Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis

Michael W Riggs, Deborah A. Schaefer, Sushila J. Kapil, Lise Barley-Maloney, Lance E. Perryman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Cryptosporidium parvum is an important cause of diarrhea in humans and calves and can persistently infect immunocompromised hosts. Presently, there are no consistently effective parasite-specific drugs for cryptosporidiosis. We hypothesized that neutralizing monoclonal antibodies (MAbs) targeting the apical complex and surface antigens CSL, GP25-200, and P23 could passively immunize against cryptosporidiosis. We recently reported that a formulation of MAbs 3E2 (anti-CSL), 3H2 (anti-GP25-200), and 1E10 (anti-P23) provided significant additive prophylactic efficacy over that of the individual MAbs in neonatal ICR mice. In the present study, these MAbs were evaluated for therapeutic efficacy against persistent infection in adult gamma interferon-depleted SCID mice. 3E2 demonstrated the most significant and consistent therapeutic effect, reducing intestinal infection in two experiments. In one experiment, 3E2 plus 3H2 and 3E2 plus 3H2 plus 1E10 also significantly reduced infection; however, no significant increase in efficacy over 3E2 alone was apparent. The results indicate that anti-CSL MAb 3E2 has highly significant efficacy in reducing, but not eliminating, persistent C. parvum infection.

Original languageEnglish (US)
Pages (from-to)275-282
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume46
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Cryptosporidiosis
Passive Immunization
Monoclonal Antibodies
Cryptosporidium parvum
Antigens
Infection
Inbred ICR Mouse
SCID Mice
Immunocompromised Host
Therapeutic Uses
Surface Antigens
Neutralizing Antibodies
Interferon-gamma
Diarrhea
Parasites
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis. / Riggs, Michael W; Schaefer, Deborah A.; Kapil, Sushila J.; Barley-Maloney, Lise; Perryman, Lance E.

In: Antimicrobial Agents and Chemotherapy, Vol. 46, No. 2, 2002, p. 275-282.

Research output: Contribution to journalArticle

Riggs, Michael W ; Schaefer, Deborah A. ; Kapil, Sushila J. ; Barley-Maloney, Lise ; Perryman, Lance E. / Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis. In: Antimicrobial Agents and Chemotherapy. 2002 ; Vol. 46, No. 2. pp. 275-282.
@article{106797ab69dc456b87d2dffa2aa50eb2,
title = "Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis",
abstract = "Cryptosporidium parvum is an important cause of diarrhea in humans and calves and can persistently infect immunocompromised hosts. Presently, there are no consistently effective parasite-specific drugs for cryptosporidiosis. We hypothesized that neutralizing monoclonal antibodies (MAbs) targeting the apical complex and surface antigens CSL, GP25-200, and P23 could passively immunize against cryptosporidiosis. We recently reported that a formulation of MAbs 3E2 (anti-CSL), 3H2 (anti-GP25-200), and 1E10 (anti-P23) provided significant additive prophylactic efficacy over that of the individual MAbs in neonatal ICR mice. In the present study, these MAbs were evaluated for therapeutic efficacy against persistent infection in adult gamma interferon-depleted SCID mice. 3E2 demonstrated the most significant and consistent therapeutic effect, reducing intestinal infection in two experiments. In one experiment, 3E2 plus 3H2 and 3E2 plus 3H2 plus 1E10 also significantly reduced infection; however, no significant increase in efficacy over 3E2 alone was apparent. The results indicate that anti-CSL MAb 3E2 has highly significant efficacy in reducing, but not eliminating, persistent C. parvum infection.",
author = "Riggs, {Michael W} and Schaefer, {Deborah A.} and Kapil, {Sushila J.} and Lise Barley-Maloney and Perryman, {Lance E.}",
year = "2002",
doi = "10.1128/AAC.46.2.275-282.2002",
language = "English (US)",
volume = "46",
pages = "275--282",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis

AU - Riggs, Michael W

AU - Schaefer, Deborah A.

AU - Kapil, Sushila J.

AU - Barley-Maloney, Lise

AU - Perryman, Lance E.

PY - 2002

Y1 - 2002

N2 - Cryptosporidium parvum is an important cause of diarrhea in humans and calves and can persistently infect immunocompromised hosts. Presently, there are no consistently effective parasite-specific drugs for cryptosporidiosis. We hypothesized that neutralizing monoclonal antibodies (MAbs) targeting the apical complex and surface antigens CSL, GP25-200, and P23 could passively immunize against cryptosporidiosis. We recently reported that a formulation of MAbs 3E2 (anti-CSL), 3H2 (anti-GP25-200), and 1E10 (anti-P23) provided significant additive prophylactic efficacy over that of the individual MAbs in neonatal ICR mice. In the present study, these MAbs were evaluated for therapeutic efficacy against persistent infection in adult gamma interferon-depleted SCID mice. 3E2 demonstrated the most significant and consistent therapeutic effect, reducing intestinal infection in two experiments. In one experiment, 3E2 plus 3H2 and 3E2 plus 3H2 plus 1E10 also significantly reduced infection; however, no significant increase in efficacy over 3E2 alone was apparent. The results indicate that anti-CSL MAb 3E2 has highly significant efficacy in reducing, but not eliminating, persistent C. parvum infection.

AB - Cryptosporidium parvum is an important cause of diarrhea in humans and calves and can persistently infect immunocompromised hosts. Presently, there are no consistently effective parasite-specific drugs for cryptosporidiosis. We hypothesized that neutralizing monoclonal antibodies (MAbs) targeting the apical complex and surface antigens CSL, GP25-200, and P23 could passively immunize against cryptosporidiosis. We recently reported that a formulation of MAbs 3E2 (anti-CSL), 3H2 (anti-GP25-200), and 1E10 (anti-P23) provided significant additive prophylactic efficacy over that of the individual MAbs in neonatal ICR mice. In the present study, these MAbs were evaluated for therapeutic efficacy against persistent infection in adult gamma interferon-depleted SCID mice. 3E2 demonstrated the most significant and consistent therapeutic effect, reducing intestinal infection in two experiments. In one experiment, 3E2 plus 3H2 and 3E2 plus 3H2 plus 1E10 also significantly reduced infection; however, no significant increase in efficacy over 3E2 alone was apparent. The results indicate that anti-CSL MAb 3E2 has highly significant efficacy in reducing, but not eliminating, persistent C. parvum infection.

UR - http://www.scopus.com/inward/record.url?scp=0036150241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036150241&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.2.275-282.2002

DO - 10.1128/AAC.46.2.275-282.2002

M3 - Article

C2 - 11796330

AN - SCOPUS:0036150241

VL - 46

SP - 275

EP - 282

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -